by jlohrconsulting | Oct 25, 2025 | Uncategorized
AAPS PharmSciTech. 2025 Oct 24;27(1):4. doi: 10.1208/s12249-025-03250-0. ABSTRACT Agomelatine (AGO) is a dual action drug. Being serotonin receptor antagonist, AGO is orally administered for depression treatment. Here in, AGO was used for intraocular pressure...
by jlohrconsulting | Oct 25, 2025 | Uncategorized
J Cancer Surviv. 2025 Oct 25. doi: 10.1007/s11764-025-01905-2. Online ahead of print. ABSTRACT PURPOSE: Internet-delivered cognitive behavioral therapies and lifestyle interventions are promising for reducing psychiatric symptoms in cancer survivors, but little is...
by jlohrconsulting | Oct 25, 2025 | Uncategorized
BMC Public Health. 2025 Oct 24;25(1):3600. doi: 10.1186/s12889-025-24845-z. ABSTRACT BACKGROUND: Māori (Indigenous) youth of Aotearoa New Zealand are experiencing widening inequities in mental health when compared to Pākehā (New Zealand European/other...
by jlohrconsulting | Oct 25, 2025 | Uncategorized
BMC Public Health. 2025 Oct 24;25(1):3591. doi: 10.1186/s12889-025-24666-0. ABSTRACT BACKGROUND: Tianeptine, a drug approved in some countries for the treatment of major depressive disorder, has raised significant public health concerns due to its potential for misuse...
by jlohrconsulting | Oct 25, 2025 | Uncategorized
BMC Pulm Med. 2025 Oct 24;25(1):487. doi: 10.1186/s12890-025-03953-x. ABSTRACT BACKGROUND: Obstructive respiratory conditions, including asthma, bronchiectasis, and chronic obstructive pulmonary disease (COPD), are increasingly recognised as heterogeneous syndromes...
Recent Comments